Medpace (NASDAQ:MEDP) CFO Kevin Brady Sells 3,400 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) CFO Kevin Brady sold 3,400 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $625.24, for a total value of $2,125,816.00. Following the transaction, the chief financial officer directly owned 12,830 shares of the company’s stock, valued at approximately $8,021,829.20. This trade represents a 20.95% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Medpace Stock Performance

MEDP traded down $0.72 during trading on Monday, reaching $620.03. 171,851 shares of the stock were exchanged, compared to its average volume of 346,791. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The stock has a market cap of $17.31 billion, a P/E ratio of 36.34, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15. The stock’s 50 day moving average price is $550.16 and its two-hundred day moving average price is $492.03.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the previous year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of recent analyst reports. Royal Bank Of Canada lifted their price objective on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. Truist Financial raised their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price target on Medpace in a report on Thursday, July 23rd. Robert W. Baird boosted their price objective on Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $584.18.

Institutional Trading of Medpace

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MEDP. California State Teachers Retirement System boosted its stake in Medpace by 53,619.6% during the second quarter. California State Teachers Retirement System now owns 13,989,649 shares of the company’s stock worth $7,408,778,000 after buying an additional 13,963,607 shares during the period. BlackRock Inc. purchased a new position in Medpace during the 2nd quarter worth $1,323,047,000. AQR Capital Management LLC lifted its stake in Medpace by 65.1% in the third quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock worth $518,170,000 after acquiring an additional 404,226 shares during the period. Madison Asset Management LLC purchased a new position in Medpace during the second quarter valued at approximately $128,956,000. Finally, Bank of America Corp DE purchased a new stake in shares of Medpace during the 2nd quarter worth $116,891,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.